deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT00006222

EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma

A Phase I Trial of EMD 121974 in Patients With HIV Related Kaposi's Sarcoma

Sponsor: National Cancer Institute (NCI)

Conditions Sarcoma
Interventions cilengitide
Updated 6 times since 2017 Last updated: May 31, 2013 Started: Sep 30, 2000 Primary completion: Mar 31, 2001 Completion: Mar 31, 2001
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Administratively complete.

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Sarcoma trials with similar outcome

Browse all Sarcoma trials

This PHASE1 trial investigates Sarcoma and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 21 months · monthly snapshotTerminated

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE1

    First recorded

Sep 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations